Author Topic: Review-Emerging Clinical Applications for Canabis & Cannabioids  (Read 4273 times)

0 Members and 1 Guest are viewing this topic.

Offline Sea Mac

  • The Wizard
  • Cultivator
  • Hero Hemp Advocate
  • *****
  • Join Date: Jan 2009
  • Posts: 474
  • Expertise: 18
  • Gender: Male
Re: Review-Emerging Clinical Applications for Canabis & Cannabioids
« Reply #2 on: 01-21-2011 at 04:08:59 AM »
Yes. Let us work WITH our natural systems, that co-evolved IN the natural world, towards optimal health!

Offline elyusium

  • Staff
  • Hemp Advocate
  • *****
  • Join Date: May 2010
  • Posts: 65
  • Expertise: 8
  • Gender: Male
Review-Emerging Clinical Applications for Canabis & Cannabioids
« Reply #1 on: 01-17-2011 at 09:27:49 AM »
The full text link at the site is very interesting read. Scientific but good science as far as I can tell.

Washington, DC: NORML made available this week the Fourth Edition of its popular and comprehensive booklet "Emerging Clinical Applications for Cannabis & Cannabinoids: A Review of the Recent Scientific Literature.

Updated and revised for 2011, this report reviews approximately 200 newly published scientific studies assessing the safety and efficacy of marijuana and its compounds in the treatment and management of nineteen clinical indications: Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), chronic pain, diabetes mellitus, dystonia, fibromyalgia, gastrointestinal disorders, gliomas and other cancers, hepatitis C, human immunodeficiency virus (HIV), hypertension, incontinence, methicillin-resistant Staphyloccus aureus (MRSA), multiple sclerosis, osteoporosis, pruritus, rheumatoid arthritis, sleep apnea, and Tourette's syndrome.

"The conditions profiled in this report were chosen because patients frequently inquire about the therapeutic use of cannabis to treat these disorders," said NORML Deputy Director Paul Armentano, the report's lead author. "In addition, many of the indications included in this report may be moderated by cannabis therapy. In several cases, preclinical data and clinical data indicates that cannabinoids may halt the progression of these diseases in a more efficacious manner than available pharmaceuticals."

The updated report also features a new section, authored by osteopath and medical cannabis specialist Dr. Dustin Sulak, highlighting the significance of the endocannabinoid system and its role in maintaining mental and physiological health.

"As we continue to sort through the emerging science of cannabis and cannabinoids, one thing remains clear: a functional cannabinoid system is essential for health," writes Dr. Sulak. "From embryonic implantation on the wall of our mother's uterus, to nursing and growth, to responding to injuries, endocannabinoids help us survive in a quickly changing and increasingly hostile environment. As I realized this, I began to wonder: can an individual enhance his/her cannabinoid system by taking supplemental cannabis? Beyond treating symptoms, beyond even curing disease, can cannabis help us prevent disease and promote health by stimulating an ancient system that is hard-wired into all of us? I now believe the answer is yes."

Full text of the report is now available online from NORML's website at: Hard copies will be available for purchase imminently. Print copies of the third edition of this report will be made available at a reduced rate for those seeking bulk orders.

For more information, please contact Paul Armentano, NORML Deputy Director, at: For more information on bulk ordering, please contact: